Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03674437 · ClinicalTrials.gov registry record

Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship

A clinical trial of Breast Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
441
Enrollment target
1
Study location

NCT03674437: Active study of Breast Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03674437 is a study of Breast Cancer Survivors that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 441 participants, below the 2,706-participant average among 8 other Breast Cancer Survivors trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03674437, a study of Breast Cancer Survivors, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
441 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to measure changes in cognitive (mental) function in cancer survivors using a brief, reliable, game-like set of tests that can be completed outside the clinic, as an alternative to traditional neurocognitive assessments. This set of computerized tests, the Cogsuite Assessment, is expected to improve our ability to identify cognitive impairments in people who have been treated for cancer, so that we can (1) learn more about which cognitive functions are affected by cancer treatment, and (2) guide that treatment more effectively.

Primary Outcome

These will include 14 correlations, across the two cohorts and 7 tests (Modified Attention Network Test, N-Back Test, Stop-signal Test, Mental Rotation Test, Verbal Fluency Test, Motor Function Test, and Processing Speed Test).

Conditions Studied

Interventions

  • BEHAVIORAL Traditional Neurocognitive Assessments
  • BEHAVIORAL Online Cognitive Battery (Cogsuite)

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 441 participants
Start Date 2018-09-11
Est. Completion 2026-09
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03674437 still lists

NCT03674437 is an observational study that tracks outcomes without assigning an intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, below the 2,706-participant average among 8 other Breast Cancer Survivors trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Breast Cancer Survivors appearing as the primary indexed condition, and to 2 interventions - of which Traditional Neurocognitive Assessments is the first listed.

NCT03674437 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03674437 about?

NCT03674437 is a clinical study titled "Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship". The purpose of this study is to measure changes in cognitive (mental) function in cancer survivors using a brief, reliable, game-like set of tests that can be completed outside the clinic, as an alternative to traditional neurocognitive assessments. This set of computerized tests, the Cogsuite Asses...

What is the current status of trial NCT03674437?

This trial is currently active not recruiting. The enrollment target is 441 participants. The study started on 2018-09-11. Estimated completion is 2026-09.

What conditions does trial NCT03674437 study?

This clinical trial studies the following conditions: Breast Cancer Survivors.

What interventions are being tested in trial NCT03674437?

The interventions under investigation include: Traditional Neurocognitive Assessments (BEHAVIORAL), Online Cognitive Battery (Cogsuite) (BEHAVIORAL).

Who is sponsoring clinical trial NCT03674437?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03674437 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Survivors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03674437's enrollment target sits among peer trials

441 3rd of 8 higher than 6 of 8 other Breast Cancer Survivors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer Survivors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02679144 · 441 participants · Phase 2

    Neuroblastoma Maintenance Therapy Trial

  • NCT03704766 · 442 participants · NA

    Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis

  • NCT04657068 · 442 participants · Phase 1

    A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • NCT05410145 · 442 participants · Phase 1

    A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03674437, the US trial registry maintained by the National Library of Medicine. NCT03674437 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.